NRXP NRX PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, NRX PHARMACEUTICALS INC reported revenue of $1.10M, net income of −$16.5M and diluted EPS of n/a; over the last four quarters revenue was $3.39M and net income −$23.5M; for the fiscal year ended December 2025 revenue was $1.23M.
NRXP annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $1.23M, gross profit n/a, operating income −$16.2M, net income −$28.6M (margin -2336.5%), EPS n/a
- Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$18.5M, net income −$25.1M (margin n/a), EPS n/a
- Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$27.8M, net income −$30.2M (margin n/a), EPS n/a
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$44.3M, net income −$39.8M (margin n/a), EPS −$0.60
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$116M, net income −$93.1M (margin n/a), EPS −$1.98
NRXP quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $1.10M, net income −$16.5M, EPS n/a
- Quarter ended Mar 31, 2026: revenue $1.07M, net income −$1.43M, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue $983K, net income $361K, EPS n/a
- Quarter ended Sep 30, 2025: revenue $242K, net income −$5.89M, EPS n/a
- Quarter ended Jun 30, 2025: revenue $0, net income −$17.6M, EPS n/a
- Quarter ended Mar 31, 2025: revenue $0, net income −$5.51M, EPS n/a
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$9.08M, EPS n/a
- Quarter ended Sep 30, 2024: revenue $0, net income −$1.62M, EPS n/a
- Quarter ended Jun 30, 2024: revenue n/a, net income −$7.90M, EPS n/a
- Quarter ended Mar 31, 2024: revenue n/a, net income −$6.53M, EPS −$0.74
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$9.86M, EPS n/a
- Quarter ended Sep 30, 2023: revenue n/a, net income −$6.06M, EPS −$0.07
- Quarter ended Jun 30, 2023: revenue n/a, net income −$8.72M, EPS −$0.12
- Quarter ended Mar 31, 2023: revenue n/a, net income −$5.51M, EPS −$1.66
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$10.2M, EPS −$0.14
- Quarter ended Sep 30, 2022: revenue n/a, net income −$9.08M, EPS −$0.14
- Quarter ended Jun 30, 2022: revenue n/a, net income −$6.98M, EPS −$0.11
- Quarter ended Mar 31, 2022: revenue n/a, net income −$13.4M, EPS −$0.21
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$30.4M, EPS −$0.14
- Quarter ended Sep 30, 2021: revenue n/a, net income −$37.0M, EPS −$0.72
NRXP cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$14.1M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$10.6M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$21.7M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$39.8M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$37.7M, share buybacks n/a
NRXP balance sheet
- Jun 30, 2026: cash $26.7M, total assets $34.2M, total liabilities $34.3M, shareholders' equity −$170K
- Mar 31, 2026: cash $6.71M, total assets $11.9M, total liabilities $25.7M, shareholders' equity −$13.8M
- Dec 31, 2025: cash $7.80M, total assets $13.0M, total liabilities $28.9M, shareholders' equity −$15.9M
- Sep 30, 2025: cash $7.18M, total assets $15.0M, total liabilities $40.8M, shareholders' equity −$25.8M
- Jun 30, 2025: cash $2.91M, total assets $4.84M, total liabilities $40.5M, shareholders' equity −$35.6M
- Mar 31, 2025: cash $5.55M, total assets $7.59M, total liabilities $32.8M, shareholders' equity −$25.2M
- Dec 31, 2024: cash $1.44M, total assets $3.65M, total liabilities $26.9M, shareholders' equity −$23.2M
- Sep 30, 2024: cash $1.65M, total assets $4.46M, total liabilities $23.3M, shareholders' equity −$18.8M
What is NRXP's revenue?
NRX PHARMACEUTICALS INC reported $3.39M of revenue over its last four quarters, through June 30, 2026.
Is NRXP profitable?
No. NRX PHARMACEUTICALS INC lost $23.5M over the last four quarters.